"First To File" Policy Increases Generics Qualifying For 180-Day Exclusivity

FDA's shift in policy to awarding 180-day exclusivity to the first generic applicant to file, rather than to the first company to successfully challenge a patent, has significantly increased the number of generics qualifying for the exclusivity.